

Pd(II) and Pt(II) trinuclear chelates with spermidine: selective anticancer activity towards TNBC-sensitive and -resistant to cisplatin

Martin Vojtek^{1,†}, Clara B. Martins^{2,†}, Raquel Ramos¹, Sara Gomes Duarte¹, Isabel M. P. L. V. O. Ferreira³, Ana L. M. Batista de Carvalho², M. Paula M. Marques^{2,4} and Carmen Diniz¹

¹ LAQV/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

² Molecular Physical-Chemistry R&D Unit, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal

³ LAQV/REQUIMTE, Laboratory of Bromatology and Hydrology, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal;

⁴ Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3000-456 Coimbra, Portugal.

Supplementary Material




Figure S1. Impact of increasing concentrations of Pd₃Spd₂ or Pt₃Spd₂ on TNBC. Dose–response curves of Pd₃Spd₂ (upper panel) and Pt₃Spd₂ (lower panel) in breast cancer MDA-MB-231 and MDA-MB-231/R cell at 24, 48 and 72 h of incubation obtained through the SRB assay. Values are expressed as mean ± SEM from 4 independent experiments (in triplicate). Data points with no visible error bars have errors smaller than the size of the symbol.